Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Villejuif
Clinical trial register · France

Clinical Trials in Villejuif, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9731 matching records held by the registry are in this view. Synced 02 Nov 2026, 03:18 UTC
9731
Studies in scope
all four open statuses
6052
Recruiting now
open to new participants
1028
Lead sponsors
across recruiting studies
Top sites
Villejuif 59 Bordeaux 20 Paris 19 Lyon 17 Angers 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris59 AstraZeneca33 Merck Sharp & Dohme LLC22 GlaxoSmithKline21 Bristol-Myers Squibb21 Clear sponsor filter
Site location
Villejuif59 Bordeaux20 Paris19 Lyon17 Angers12
All 63 locations
Target enrolment
to

Trials with a site in Villejuif

59 of 9731 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Not yet open
Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma
NCT07802652Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
DrugsDT-7012·Doxorubicin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
80
Villejuif
2027-02-01
Not yet open
Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma.
NCT07808567Pancreatic Adenocarcinoma Resectable, Non Metastatic, ECOG Performance Status Score of 0 or 1
DrugsFolfirinox·Nab-paclitaxel·Gemcitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
42
Villejuif
2027-01
Not yet open
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
NCT07544225Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Sjogren's Disease With Dry Eyes, Systemic Sclerosis (SSc)
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
6
Villejuif
2026-12-01
Not yet open
Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer
NCT07591467BRCA-Mutated, Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer, Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
330
Bordeaux, Lyon, Marseille, Nancy, Villejuif
2026-09
Not yet open
Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced Sonication
NCT07754006Recurrent Grade 4 Glioma, Brain Metastases From Extra-cranial Solid Tumors
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
6
Villejuif
2026-09
Not yet open
Adjuvant Trial in Pancreatic Neuroendocrine Tumors
NCT07591493Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Neuroendocrine Tumors
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
300
Villejuif
2026-09
Not yet open
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4
794
Villejuif
2026-09
Not yet open
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
24
Villejuif, Bordeaux
2026-07
Recruiting
Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer
NCT07436312Breast Cancer, Pancreas Cancer, Colon Cancer, Lynch Syndrome
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
170
Avignon, Rennes, Villejuif
2026-05-04
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
60
Villejuif, Bordeaux, Dijon, Marseille, Paris, Saint-Herblain, Vandœuvre-lès-Nancy
2026-03-25
Recruiting
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals
NCT06907095Risk of Breast Cancer, Risk of Gynaecological Cancer, Risk of Colorectal Cancer, Risk of Upper Gastrointestinal Cancers
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
5,909
Villejuif
2026-03-16
Recruiting
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
NCT07303387Solid Tumor Malignancies, Clear Cell Endometrial Carcinoma, Ovarian Cancer
DrugValemetostat Tosylate
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
900
Villejuif, Bordeaux, Lyon, Paris
2026-03-05
Not yet open
Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer
NCT06787118Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, HR+ Breast Cancer
DrugCBD oil
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
130
Villejuif
2025-12
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
162
Dijon, Grenoble, Paris, Suresnes, Toulon, Villejuif
2025-11-17
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
140
Villejuif
2025-10-06
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
180
Villejuif
2025-09-09
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
124
Creil, Avignon, Villejuif
2025-09-09
Recruiting
STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue
NCT06505590Cancer Diagnosis, Moderate or Severe Score of Cancer-related Fatigue (CRF)
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
372
Villejuif
2025-09-01
Not yet open
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
262
Villejuif
2025-09
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
40
Bordeaux, Nice, Villejuif
2025-07-02
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4
50
Angers, Dijon, Lyon, Paris, Toulouse, Tours, Villejuif
2025-05-16
Not yet open
Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood
NCT06957132Ototoxicity, Drug-Induced, Ototoxicity, Radiation-Induced, Pediatric Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
500
Paris, Villejuif
2025-05
Recruiting
tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
NCT06332274Cancer, Lung Cancer, Colo-rectal Cancer, Pancreas Cancer
DrugTislelizumab
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
717
Villejuif
2025-04-16
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
40
Villejuif
2024-09-30
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2
58
Lyon, Villejuif
2024-07-11
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2
50
Villejuif
2024-07-05
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
212
Avignon, Lyon, Marseille, Mâcon, Nice, Saint-Etienne, Saint-Herblain, Villejuif
2024-03-26
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2
152
Villejuif
2024-03-21
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Observational
700
Villejuif
2024-01-11
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
78
Lyon, Villejuif
2023-12-19
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1
23
Bordeaux, Lille, Lyon, Paris, Villejuif
2023-06-16
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
180
Villejuif
2023-05-31
Recruiting
Engineering Immune Organoids to Study Pediatric Cancer
NCT05890781Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma
DrugBlood sample
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
108
Villejuif, Paris
2023-05-12
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
150
Villejuif
2023-05-05
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
40
Lyon, Marseille, Paris, Villejuif
2022-12-13
Recruiting
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
NCT05476939Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
DrugsDordaviprone·Everolimus
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
433
Villejuif, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand
2022-09-29
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
160
Villejuif
2022-06-08
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
200
Bordeaux, Lyon, Villejuif
2021-12-06
Active, closed
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
NCT04940325Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer
DrugDato-DXd
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
100
Bordeaux, Brest, Caen, Créteil, Paris, Pierre-Bénite, Strasbourg, Villejuif
2021-05-12
Recruiting
Gustave Roussy Cancer Profiling
NCT04932525Solid Tumor, Unspecified, Adult
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
20,000
Villejuif, Le Plessis-Robinson, Paris, Suresnes
2021-05-10
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
65
Villejuif
2020-12-15
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Observational
1,150
Villejuif, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand
2020-04-09
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
DrugsDinutuximab beta·Vindesine·Cyclophosphamid·Thiotepa
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
800
Villejuif, Amiens, Angers, Besançon, Bordeaux, Brest, Caen, Clermont-Ferrand
2019-11-05
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
1,210
Villejuif, Besançon, Cergy-Pontoise, Clermont-Ferrand, Fort de France, Guadeloupe, Mougins, Nice
2019-06-06
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
45
Paris, Villejuif, Bordeaux, Créteil, Lille, Lyon, Toulouse, Vandœuvre-lès-Nancy
2019-01-02
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
1,240
Villejuif, Chevilly-Larue, Le Kremlin-Bicêtre, Le Plessis-Robinson
2018-12-12
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
315
Villejuif, Lille, Paris, Rennes
2018-08-29
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
352
Villejuif, Angers, Bordeaux, Bron, Caen, Clermont-Ferrand, Dijon, Haguenau
2018-08-08
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Observational
150
Villejuif, Créteil, Lille, Lyon, Marseille, Montpellier, Nantes, Nice
2018-06-22
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
500
Villejuif, Paris
2018-06-14
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
60
Villejuif
2018-05-28
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
140
Villejuif
2018-02-12
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
197
Villejuif
2018-01-17
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Not applicable
350
Villejuif
2016-09-26
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2
472
Villejuif, Angers, Bordeaux, Lille, Lyon, Marseille, Nantes, Paris
2016-08-03
Recruiting
Neurocognitive Risks in Children With Solid Tumors
NCT03609112Solid Tumor in Children
Gustave Roussy, Cancer Campus, Grand Paris
Observational
1,000
Villejuif
2014-10-01
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
154
Villejuif, Avignon, Caen, Dijon, Lille, Marseille, Montpellier, Nice
2014-02-26
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Observational
10,000
Villejuif, Lyon, Paris
2013-07-23
Active, closed
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
776
Villejuif
2013-05-13
Rows per page Showing 1–59 of 59
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 2 November 2026. https://priyalifescience.com/clinical-trials-france/city/villejuif

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,731 studies in total at the last sync on 02 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 59 of those studies with a site in Villejuif that also match the filters currently applied.

How many clinical trials are recruiting in Villejuif?

37 of the 59 studies on this page are recruiting new participants as of the 02 Nov 2026, 03:18 UTC sync. A further 11 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Villejuif), 59 studies
PhaseStudiesRecruitingShare
Phase 316827.1%
Phase 215825.4%
Not applicable131022%
Observational558.5%
Phase 1416.8%
Phase 1/2446.8%
Phase 4213.4%

Most active sponsors

Lead sponsors with the most studies (Villejuif)
Lead sponsorStudiesRecruiting
Gustave Roussy, Cancer Campus, Grand Paris5937
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.